TSR-033 + dostarlimab + mFOLFOX6 + bevacizumab

**TSR-033 + dostarlimab + mFOLFOX6 + bevacizumab** is an investigational combination chemotherapy and immunotherapy regimen under clinical evaluation, primarily for colorectal and gastrointestinal cancers. It consists of: - **TSR-033**: A monoclonal antibody targeting the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) to enhance anti-tumor immune response. - **Dostarlimab**: A monoclonal antibody against programmed death receptor-1 (PD-1), serving as a checkpoint inhibitor to promote T-cell mediated anti-tumor activity. - **mFOLFOX6**: A well-characterized chemotherapy protocol for colorectal cancer that includes oxaliplatin, leucovorin (folinic acid), and fluorouracil (5-FU). - **Bevacizumab**: A monoclonal antibody inhibiting vascular endothelial growth factor A (VEGF-A), which reduces tumor angiogenesis. This combination aims to leverage cytotoxic chemotherapy (mFOLFOX6), anti-angiogenesis (bevacizumab), and dual checkpoint blockade (TSR-033 and dostarlimab) to enhance anti-tumor efficacy.